This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses. Continue to STAT+ to read the full story…
Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.
Effective management of immune checkpoint inhibitor-related toxicities requires early intervention, evolving guideline adherence, and multidisciplinary collaboration, with steroids remaining a key treatment.
PD-L1 immune checkpoint inhibitors are now standard for early-stage non-metastatic non-small cell lung cancer (NSCLC), with neoadjuvant, adjuvant, and perioperative strategies improving survival and outcomes.
Christine Barrett, PharmD, BCOP, addressed advances in the treatment of stage III melanoma that provide the potential to improve long-term outcomes by enhancing immune response, tailoring surgical approaches, and refining patient selection strategies.
The AACR Immunotherapy Conference 2025 will provide pharmacists with the opportunity to engage with cutting-edge cancer immunotherapy research, explore advancements in treatments, such as immune checkpoint inhibitors and CAR T-cell therapy, and connect with key leaders in the field.
. | By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday.
Understanding the Impact of Guillain-Barr syndrome Pradip Mahajan Mon, 01/27/2025 - 15:41 Guillain-Barre syndrome (GBS) is an autoimmune disease. It's a rare neurological disorder that occurs when the body's immune system attacks its own peripheral nerves that carry signals from the brain and spinal cord to the rest of the body.
The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition.
According to the FDA announcement, the most serious side effect of Wezlana is infection because the prescription affects your immune response. Reuters reported that the settlement terms were confidential but would allow Amgen to begin selling its biosimilar of Stelara no later than January 1, 2025. How much will Wezlana cost?
billion in 2025 for the entire Medicare program, a spokesperson for the Centers for Medicare and Medicaid Services confirmed. These include oxytocin, which is used during childbirth; Rho(D) immune globulin, which helps some women during pregnancy; standard-of-care chemotherapy, pain and sedation medicines; and ADHD pills.
Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.
As part of this work, PQA has launched a proof-of-concept pilot using several PQA pharmacy measure concepts to evaluate the effectiveness of pharmacies in improving adult immunization rates through value-based arrangements (VBA) with payers. Submissions for poster abstract proposals are due Friday, January 10, 2025. Learn more.
This product is designed to support the rapid reproduction of beneficial bacteria throughout the small and large intestines, to promote healthy gastrointestinal and immune function. Research has shown that the cat’s claw plant may have antiviral, anti-inflammatory, antioxidant, and immune-modulating properties.
Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership. Individuals with weak immune systems could have severe symptoms, and congenitally infected babies could suffer from an intellectual disability and vision and hearing loss.
2 These are cells commonly found in the stroma of the tumour, which play an important role in inhibiting the body’s own immune response to the tumour, mediated through CD8+ T-cells (tumour-infiltrating lymphocytes). Research in the last few years has shown NOX4 in tumour cells is linked to the growth of cancer-associated fibroblasts (CAFs).
The UK has also taken an option on another 40 million doses in 2022, and between 30 and 90 million until 2025. The hope is that directly targeting the cells lining the airways may stimulate a more effective immune response against SARS-CoV-2. If exercised, that second phase would be worth €900 million to the French biotech.
Type 1 diabetes occurs when your immune system prevents your pancreas from producing enough insulin. The 2020–2025 Dietary Guidelines for Americans recommend that Americans limit the amount of sugar they consume to less than 10% of their daily intake of calories. Does sugar cause diabetes?
Cost highlighted progress towards completion of PQA’s strategic plan, Blueprint PQA 2025. By participating in PQA pilots, some organizations have been able to identify successful pharmacy interventions and make plans for 2025 and beyond. Save the date to join us at the 2025 PQA Annual Meeting, May 19-21 in Tampa! Sign
Apexigen discovers and develops a new generation of antibody therapeutics to treat cancer, along with new immuno-oncology products to harness the immune system to combat and eradicate cancer. Pyxis Oncology will issue 0.1725 shares of its common stock, with par value of $0.001 per share, for each Apexigen share.
are wrapping up year four of Blueprint PQA 2025, PQAs five-year strategic plan. This two-year project will begin in early 2025. That work will continue in 2025. This fall, we launched a pilot to evaluate the effectiveness of pharmacies in improving adult immunization rates through VBAs with payers.
Under the agreement, Calico is responsible for research and early development until 2025 and will take projects through phase 2a trials until 2030, with AbbVie having an option to take over projects once they reach later-stage development and lead commercialisation efforts.
This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Topline data from Vera’s ORIGIN Phase III trial of atacicept is expected in the first half of 2025. IgAN is the most common primary glomerulonephritis worldwide.
This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function. Topline data from Vera’s ORIGIN Phase III trial of atacicept is expected in the first half of 2025. IgAN is the most common primary glomerulonephritis worldwide.
We continue to play a central role in driving meaningful improvements and positive changes related to medication safety, adherence and appropriate use.The 2023 PQA Annual Report documents our progress towards Blueprint PQA 2025. There are still numerous opportunities to be involved with PQA and impact quality medication use in 2023.
It may help protect against heart disease, improve immunity, and more. According to the Dietary Guidelines for Americans 2020–2025 , a healthy eating plan emphasizes fruit, vegetables, whole grains, lean protein, and low-fat dairy. They are also a source of folate, B vitamins, vitamin K, calcium, magnesium, and potassium.
For example, the 2020-2025 Dietary Guidelines for Americans promote a plant-based diet rich in fruits, vegetables, whole grains, and legumes and low in red and processed meats, saturated fats, and alcohol. They are believed to support optimal digestion, boost immune system function, and provide essential nutrients for overall health.
That’s the first objective of goal one of PQA Blueprint 2025, our strategic plan. In the coming weeks, we will launch a new pilot to address adult immunization status and gaps in payer-pharmacy arrangements. We’re making tremendous progress, but realizing this goal will take years to fully achieve.
Analysts at Mizuho have suggested that competition from BMS’ drug could trim Otezla’s 2025 sales from $3 billion to $2 billion, although Amgen is attempting to defend its product by expanded the label of the drug to include mild psoriasis. Otezla was acquired by Amgen for $13.4
They are designed to recognize and bind to two specific molecules, such as a tumor cell and an immune cell, or two different parts of the same molecule. Bispecific antibodies are a type of antibody that can bind to two different targets at the same time. during the period 2023-2035.
Firstly, alpha particles exhibit greater biological effectiveness by inducing irreparable DNA double-strand breaks, minimising the risk of resistance or immune escape in tumour cells. However, by employing alpha particles, TAT offers two crucial advantages.
1 Every year, 19,500 people are diagnosed with lymphoma 2 – a cancer affecting a certain type of white blood cell within the immune system – and can be classed as either slow or fast growing. Our strategy for 2020-2025: Changing how people live with lymphoma. Despite being relatively common, lymphoma is often challenging to diagnose.
The company’s patch technology delivers trace amounts of allergens to build an immune response. DBV expects to share topline data from the study in H1 2025. According to the company’s January 2023 corporate presentation, there are 280,000 toddlers and 390,000 children living with peanut allergy in the US.
And when you set the right goals, 2025 could be the year you finally break free from PBM madness, build a loyal patient base, and boost your pharmacy profits. For example, if your goal is to grow your immunization program, don’t just say, “I want to do more vaccines.” What Will You Accomplish in 2025?
1] This inability to detox properly can trigger or worsen autoimmune symptoms, as these chemical exposures can trigger immune dysregulation. [2] Reduced inflammation and joint pain Toxins can trigger the immune system, leading to chronic inflammation, joint pain, and autoimmune flares. Accessed February 20, 2025. 3] Faber S.
Over the last three years, we have been investigating how the body’s immune cells (which are usually the body’s natural defence system against infection) can actually play a role in driving tumour growth. Sporadic and NF2 VS are highly similar, specific macrophages found in growing VS, meningioma and VS have different immune profiles.
Cytokines have long been investigated for their potential as cancer treatments – selectively stimulate tumour-fighting immune cells – with varying levels of success. Trutino’s lead in-house asset is in early-stage development and scheduled to start clinical testing in solid tumours in 2025.
Kelly Goode, PharmD, BCPS, FAPhA, FCCP, professor in the department of pharmacotherapy and outcomes science at Virginia Commonwealth University, discusses the current landscape of immunization recommendations.
… Moderna announced that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines targeting those viruses , STAT says. A combo shot could improve uptake of both flu and Covid vaccines.
Prior to CheckMate-274, no immune checkpoint inhibitor had shown efficacy as adjuvant therapy for these patients, and BMS could have some time on its own in the category. Cisplatin is sometimes used to reduce the tumour before surgery or as adjuvant treatment afterwards, but there isn’t much data to support its benefit in invasive UC.
Similar to how we injected mRNA into people to trigger an immune response and train their immune system against COVID-19, genomic medicine repairs cellular or molecular mechanisms that are dysfunctional and cause disease.”. By 2025, pharma’s investment in AI is expected to reach $3 billion.
Everyone agrees that cell and gene therapies are poised for an explosion, with far more drugs in the pipeline than are currently approved, and the FDA predicts it will clear 10 to 20 per year by 2025. These therapies have incredible potential to fight cancer and other diseases using the patient’s own immune system.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content